Form Type: 4

SEC EDGAR Link
Acccession Number:0001209191-19-045973
Date:2019-08-12
Issuer: FIBROGEN INC (FGEN)
Original Submission Date:

Reporting Person:

NEFF THOMAS B
C/O FIBROGEN, INC.
409 ILLINOIS ST. SAN FRANCISCO, CA 94158

Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
Title of SecurityTransaction Date2a. Deemed Execution Date Transaction CodeSharesAcquired or DisposedPrice per share 5. Amount of Securities Beneficially Owned Following Reported Transaction 6. Ownership Form Direct or IndirectNature of Indirect Ownership
COMMON STOCK 0 $0.00 20,000 indirect
COMMON STOCK 0 $0.00 60,946 indirect f10
COMMON STOCK 2019-08-12 S 300 d $45.67 48,492 indirect
COMMON STOCK 2019-08-13 S 500 d $46.17 47,074 indirect
COMMON STOCK 2019-08-13 S 918 d $45.31 47,574 indirect
COMMON STOCK 2019-08-12 S 1,118 d $45.04 48,792 indirect
COMMON STOCK 2019-08-12 M 6,834 a $2.90 2,379,710 direct
COMMON STOCK 2019-08-13 M 6,834 a $2.90 2,368,144 direct
COMMON STOCK 2019-08-13 S 6,900 d $46.19 2,349,744 direct
COMMON STOCK 2019-08-12 S 7,700 d $45.59 2,361,310 direct
COMMON STOCK 2019-08-12 S 10,700 d $44.98 2,369,010 direct
COMMON STOCK 2019-08-13 S 11,500 d $45.33 2,356,644 direct
Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, convertible securities
Title of Derivative Security Conversion or Exercise Price of Derivative Security Transaction Date Deemed Execution Date Transaction Code Number of Derivative Securities Acquired (A) or Disposed of (D) Date ExercisableExpiration Date Title and Amount of Securities Underlying Derivative Security Price of Derivative Security Number of derivative Securities Beneficially Owned Following Reported Transaction(s) Ownership Form: Direct (D) or Indirect (I) Nature of Indirect Beneficial Ownership
STOCK OPTION (RIGHT TO BUY) 2.9 2019-08-12 deemed execution date M 6,834 (d) 2020-06-09 common stock 6,834 $2.90 198,204 direct
STOCK OPTION (RIGHT TO BUY) 2.9 2019-08-13 deemed execution date M 6,834 (d) 2020-06-09 common stock 6,834 $2.90 191,370 direct
Footnotes
IDfootnote
f1 shares sold pursuant to a 10b5-1 plan.
f2 the shares were sold at prices ranging from $44.42 to $45.41. the reporting person will provide upon request to the sec, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
f3 the shares were sold at prices ranging from $45.42 to $45.90. the reporting person will provide upon request to the sec, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
f4 the shares were sold at prices ranging from $44.50 to $45.46. the reporting person will provide upon request to the sec, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
f5 the shares were sold at prices ranging from $45.515 to $45.76. the reporting person will provide upon request to the sec, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
f6 the shares were sold at prices ranging from $44.94 to $45.93. the reporting person will provide upon request to the sec, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
f7 the shares were sold at prices ranging from $45.94 to $46.60. the reporting person will provide upon request to the sec, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
f8 the shares were sold at prices ranging from $44.98 to $45.82. the reporting person will provide upon request to the sec, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
f9 the shares were sold at prices ranging from $46.00 to $46.37. the reporting person will provide upon request to the sec, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
f10 the shares are held by biogrowth partners, lp. the reporting person is the sole general partner of biogrowth partners, lp and has sole voting and dispositive power over the shares held by biogrowth partners, lp.
f11 fully vested.

Elevate your investments